Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.1.1 THREAT OF NEW ENTRANTS
4.1.2 THREAT OF SUBSTITUTES
4.1.3 BARGAINING POWER OF BUYERS
4.1.4 BARGAINING POWER OF SUPPLIERS
4.1.5 INDUSTRY RIVALRY
4.2 BRAND OUTLOOK
4.3 COST ANALYSIS BREAKDOWN
4.3.1 DRUG ACQUISITION COSTS AND PRICING DYNAMICS
4.3.2 MANUFACTURING AND BIOLOGICS PRODUCTION COSTS
4.3.3 RESEARCH AND DEVELOPMENT EXPENDITURE
4.3.4 DISTRIBUTION, LOGISTICS, AND COLD CHAIN MANAGEMENT
4.3.5 ADMINISTRATION AND HEALTHCARE SYSTEM COSTS
4.3.6 IMPACT OF BIOSIMILARS AND COMPETITIVE PRICING
4.3.7 REIMBURSEMENT FRAMEWORKS AND PATIENT ACCESS
4.3.8 MARKET DEVELOPMENTS INFLUENCING COST STRUCTURES
4.3.9 CONCLUSION
4.4 INDUSTRY ECOSYSTEM ANALYSIS
4.4.1 OVERVIEW OF THE INDUSTRY ECOSYSTEM STRUCTURE
4.4.2 DRUG DISCOVERY AND TRANSLATIONAL RESEARCH ECOSYSTEM
4.4.3 CLINICAL DEVELOPMENT AND TRIAL INFRASTRUCTURE
4.4.4 MANUFACTURING AND BIOPHARMACEUTICAL SUPPLY CHAIN ECOSYSTEM
4.4.5 REGULATORY AND HEALTH AUTHORITY ECOSYSTEM
4.4.6 HEALTHCARE DELIVERY AND PRESCRIBING ECOSYSTEM
4.4.7 DISTRIBUTION AND PHARMACEUTICAL ACCESS CHANNELS
4.4.8 PATIENT ADVOCACY AND DISEASE AWARENESS ECOSYSTEM
4.4.9 PRICING AND MARKET ACCESS ECOSYSTEM
4.5 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.5.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.5.1.1 JOINT VENTURES
4.5.1.2 MERGERS AND ACQUISITIONS
4.5.1.3 LICENSING AND PARTNERSHIP
4.5.1.4 TECHNOLOGY COLLABORATIONS
4.5.1.5 STRATEGIC DIVESTMENTS
4.5.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.5.3 STAGE OF DEVELOPMENT
4.5.4 TIMELINES AND MILESTONES
4.5.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.5.6 RISK ASSESSMENT AND MITIGATION
4.5.7 FUTURE OUTLOOK
4.6 PATENT ANALYSIS
4.6.1 PATENT QUALITY AND STRENGTH
4.6.2 COUNTRY PATENT LANDSCAPE.
4.6.3 IP STRATEGY AND MANAGEMENT
4.6.4 LICENSING AND COLLABORATION
4.7 PRICING ANALYSIS
4.7.1 PREMIUM PRICING STRUCTURE DOMINATED BY BIOLOGICS AND TARGETED THERAPIES
4.7.2 BIOLOGICS AS THE KEY REVENUE AND PRICE REALIZATION SEGMENT
4.7.3 LOW-COST VOLUME SEGMENT LED BY NSAIDS AND CONVENTIONAL THERAPIES
4.7.4 REGIONAL PRICING DISPARITY ACROSS MIDDLE EAST AND AFRICA MARKETS
4.7.5 BIOSIMILARS DRIVING DOWNWARD PRICE CORRECTION
4.7.6 HEALTH ECONOMIC BURDEN AND PAYER-DRIVEN PRICING PRESSURE
4.8 PROFIT MARGINS SCENARIO
4.8.1 OVERVIEW OF PROFIT MARGIN DYNAMICS
4.8.2 REVENUE STRUCTURE AND PRICING POWER IN BIOLOGIC THERAPIES
4.8.3 COST STRUCTURE AND MANUFACTURING ECONOMICS
4.8.4 IMPACT OF BIOSIMILARS AND COMPETITIVE EROSION
4.8.5 REGIONAL REIMBURSEMENT AND MARKET ACCESS INFLUENCE
4.8.6 PIPELINE INNOVATION AND MARGIN EXPANSION POTENTIAL
4.8.7 REGULATORY APPROVALS AND MARKET EXPANSION CONTEXT
4.8.8 COMPETITIVE AND CLINICAL ADOPTION DYNAMICS
4.8.9 INNOVATION-DRIVEN MARGIN SUSTAINABILITY
4.8.10 CONCLUSION
4.9 RAW MATERIAL COVERAGE
4.9.1 OVERVIEW OF RAW MATERIAL LANDSCAPE
4.9.2 BIOLOGIC ACTIVE INGREDIENT PRODUCTION INPUTS
4.9.3 CELL CULTURE MEDIA AND UPSTREAM PROCESSING MATERIALS
4.9.4 CHROMATOGRAPHY AND PURIFICATION MATERIALS
4.9.5 FORMULATION EXCIPIENTS AND STABILIZATION AGENTS
4.9.6 PRIMARY PACKAGING MATERIALS
4.9.7 SECONDARY PACKAGING AND COLD CHAIN LOGISTICS MATERIALS
4.9.8 QUALITY STANDARDS AND REGULATORY MATERIAL COMPLIANCE
4.9.9 SUPPLY CHAIN CONSTRAINTS AND RISK FACTORS
4.9.10 EMERGING TRENDS IN RAW MATERIAL INNOVATION
4.1 TECHNOLOGICAL ADVANCEMENTS
4.10.1 EVOLUTION OF TARGETED BIOLOGIC THERAPIES
4.10.2 EMERGENCE OF IL-17 INHIBITORS AND NOVEL MECHANISTIC PATHWAYS
4.10.3 ADVANCEMENT OF ORAL SMALL MOLECULE THERAPIES
4.10.4 BIOMARKER-DRIVEN DIAGNOSIS AND TREATMENT OPTIMIZATION
4.10.5 DIGITAL HEALTH INTEGRATION AND REMOTE MONITORING
4.10.6 ADVANCES IN DRUG DELIVERY SYSTEMS
4.10.7 ONGOING RESEARCH IN NEXT-GENERATION THERAPEUTICS
4.10.8 INTEGRATION OF PRECISION MEDICINE APPROACHES
4.10.9 CONCLUSION
4.11 VALUE CHAIN ANALYSIS
4.11.1 RAW MATERIALS AND ACTIVE PHARMACEUTICAL INGREDIENTS
4.11.2 DRUG DISCOVERY AND PRECLINICAL DEVELOPMENT
4.11.3 MANUFACTURING AND BIOPROCESSING
4.11.4 PROCESSING, FILL-FINISH AND STERILIZATION
4.11.5 PACKAGING AND LABELING
4.11.6 DISTRIBUTION AND LOGISTICS
4.11.7 CONCLUSION
4.12 VENDOR SELECTION CRITERIA
4.12.1 CLINICAL EFFICACY AND EVIDENCE-BASED DIFFERENTIATION
4.12.2 MECHANISM OF ACTION AND PORTFOLIO BREADTH
4.12.3 REGULATORY COMPLIANCE AND MIDDLE EAST AND AFRICA MARKET ACCESS
4.12.4 PRICING STRATEGY AND REIMBURSEMENT LANDSCAPE
4.12.5 MANUFACTURING CAPABILITIES AND SUPPLY CHAIN RELIABILITY
4.12.6 STRATEGIC COLLABORATIONS AND INNOVATION CAPACITY
4.12.7 REAL-WORLD EVIDENCE AND POST-MARKETING SURVEILLANCE
4.12.8 MARKET PRESENCE AND PHYSICIAN ENGAGEMENT
4.12.9 CONCLUSION
5 TARIFFS & IMPACT ON THE MARKET
5.1 CURRENT TARIFF RATE(S) IN TOP-5 COUNTRY MARKETS
5.2 OUTLOOK: LOCAL PRODUCTION VERSUS IMPORT RELIANCE
5.3 VENDOR SELECTION CRITERIA DYNAMICS
5.4 IMPACT ON SUPPLY CHAIN
5.4.1 RAW MATERIAL PROCUREMENT
5.4.2 MANUFACTURING AND PRODUCTION
5.4.3 LOGISTICS AND DISTRIBUTION
5.4.4 PRICE PITCHING AND MARKET POSITION
5.5 INDUSTRY PARTICIPANTS: PROACTIVE MOVES
5.5.1 SUPPLY CHAIN OPTIMIZATION
5.5.2 JOINT VENTURE ESTABLISHMENTS
6 REGULATORY FRAMEWORK AND APPROVAL PATHWAYS
6.1 OVERVIEW
6.2 REGIONAL REGULATORY AND REIMBURSEMENT LANDSCAPES
6.3 PRICING, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE
6.4 POST-MARKETING SURVEILLANCE AND PHARMACOVIGILANCE
7 MARKET OVERVIEW
7.1 DRIVER
7.1.1 INCREASING PREVALENCE OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND IMPROVED DISEASE AWARENESS
7.1.2 GROWING ADOPTION OF BIOLOGICS SUCH AS TNF INHIBITORS AND IL-17 INHIBITORS FOR EARLY-STAGE TREATMENT
7.1.3 ADVANCEMENTS IN DIAGNOSTIC TECHNIQUES ENABLING EARLIER AND MORE ACCURATE DETECTION
7.1.4 RISING HEALTHCARE EXPENDITURE AND IMPROVED ACCESS TO SPECIALTY CARE IN EMERGING MARKETS
7.2 RESTRAINT
7.2.1 HIGH COST OF BIOLOGIC THERAPIES LIMITING PATIENT ACCESS IN LOW- AND MIDDLE-INCOME REGIONS
7.2.2 STRINGENT REGULATORY APPROVAL PROCESSES FOR NOVEL THERAPEUTICS DELAYING MARKET ENTRY
7.3 OPPORTUNITIES
7.3.1 DEVELOPMENT OF TARGETED THERAPIES AND NOVEL BIOLOGICS WITH IMPROVED EFFICACY AND SAFETY PROFILES
7.3.2 EXPANSION OF BIOSIMILARS MARKET REDUCING TREATMENT COSTS AND IMPROVING ACCESSIBILITY
7.3.3 GROWING FOCUS ON PERSONALIZED MEDICINE AND PRECISION THERAPEUTICS
7.4 CHALLENGES
7.4.1 COMPLEXITY IN DISEASE DIAGNOSIS DUE TO LACK OF RADIOGRAPHIC EVIDENCE IN EARLY STAGES
7.4.2 PATIENT ADHERENCE ISSUES DUE TO CHRONIC NATURE OF TREATMENT
8 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
8.2.1 NORTH AMERICA
8.2.2 EUROPE
8.2.3 ASIA-PACIFIC
8.2.4 SOUTH AMERICA
8.2.5 MIDDLE EAST & AFRICA
8.3 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
8.3.1 MEDICATION
8.3.2 SURGERY
8.3.3 PHYSICAL THERAPY
8.3.4 OTHERS
8.4 MIDDLE EAST AND AFRICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.4.1 BIOLOGICS
8.4.2 NSAIDS
8.4.3 ANALGESICS
8.4.4 DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)
8.4.5 OTHERS
8.5 MIDDLE EAST AND AFRICA BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.5.1 TNF INHIBITORS
8.5.2 INTERLEUKIN (IL-17) INHIBITORS
8.5.3 JAK INHIBITORS
8.5.4 OTHERS
8.6 MIDDLE EAST AND AFRICA TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.6.1 ADALIMUMAB
8.6.2 ETANERCEPT
8.6.3 CERTOLIZUMAB PEGOL
8.6.4 INFLIXIMAB
8.6.5 OTHERS
8.7 MIDDLE EAST AND AFRICA INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.7.1 SECUKINUMAB
8.7.2 IXEKIZUMAB
8.7.3 OTHERS
8.8 MIDDLE EAST AND AFRICA JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.8.1 UPADACITINIB
8.8.2 TOFACITINIB
8.8.3 OTHERS
8.9 MIDDLE EAST AND AFRICA NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.9.1 TRADITIONAL NSAIDS
8.9.2 SELECTIVE COX-2 INHIBITORS
8.9.3 OTHERS
8.1 MIDDLE EAST AND AFRICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
8.10.1 NORTH AMERICA
8.10.2 EUROPE
8.10.3 ASIA-PACIFIC
8.10.4 SOUTH AMERICA
8.10.5 MIDDLE EAST AND AFRICA
8.11 MIDDLE EAST AND AFRICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.11.1 JOINT REPLACEMENT
8.11.2 SPINAL FUSION
8.11.3 OTHERS
8.12 MIDDLE EAST AND AFRICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
8.12.1 NORTH AMERICA
8.12.2 EUROPE
8.12.3 ASIA-PACIFIC
8.12.4 SOUTH AMERICA
8.12.5 MIDDLE EAST AND AFRICA
8.13 MIDDLE EAST AND AFRICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.13.1 EXERCISE-BASED APPROACHES
8.13.2 HYDROTHERAPY
8.13.3 OTHERS
8.14 MIDDLE EAST AND AFRICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
8.14.1 NORTH AMERICA
8.14.2 EUROPE
8.14.3 ASIA-PACIFIC
8.14.4 SOUTH AMERICA
8.14.5 MIDDLE EAST AND AFRICA
8.15 MIDDLE EAST AND AFRICA OTHER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
8.15.1 NORTH AMERICA
8.15.2 EUROPE
8.15.3 ASIA-PACIFIC
8.15.4 SOUTH AMERICA
8.15.5 MIDDLE EAST AND AFRICA
9 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG
9.1 OVERVIEW
9.2 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
9.2.1 ADALIMUMAB
9.2.2 SECUKINUMAB
9.2.3 ETANERCEPT
9.2.4 IXEKIZUMAB
9.2.5 UPADACITINIB
9.2.6 CERTOLIZUMAB PEGOL
9.2.7 GOLIMUMAB
9.2.8 INFLIXIMAB
9.2.9 TOFACITINIB
9.2.10 OTHERS
9.3 MIDDLE EAST AND AFRICA ADALIMUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.3.1 NORTH AMERICA
9.3.2 EUROPE
9.3.3 ASIA-PACIFIC
9.3.4 SOUTH AMERICA
9.3.5 MIDDLE EAST AND AFRICA
9.4 MIDDLE EAST AND AFRICA SECUKINUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.4.1 NORTH AMERICA
9.4.2 EUROPE
9.4.3 ASIA-PACIFIC
9.4.4 SOUTH AMERICA
9.4.5 MIDDLE EAST AND AFRICA
9.5 MIDDLE EAST AND AFRICA ETANERCEPT IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.5.1 NORTH AMERICA
9.5.2 EUROPE
9.5.3 ASIA-PACIFIC
9.5.4 SOUTH AMERICA
9.5.5 MIDDLE EAST AND AFRICA
9.6 MIDDLE EAST AND AFRICA IXEKIZUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.6.1 NORTH AMERICA
9.6.2 EUROPE
9.6.3 ASIA-PACIFIC
9.6.4 SOUTH AMERICA
9.6.5 MIDDLE EAST AND AFRICA
9.7 MIDDLE EAST AND AFRICA UPADACITINIB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.7.1 NORTH AMERICA
9.7.2 EUROPE
9.7.3 ASIA-PACIFIC
9.7.4 SOUTH AMERICA
9.7.5 MIDDLE EAST AND AFRICA
9.8 MIDDLE EAST AND AFRICA CERTOLIZUMAB PEGOL IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.8.1 NORTH AMERICA
9.8.2 EUROPE
9.8.3 ASIA-PACIFIC
9.8.4 SOUTH AMERICA
9.8.5 MIDDLE EAST AND AFRICA
9.9 MIDDLE EAST AND AFRICA GOLIMUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.9.1 NORTH AMERICA
9.9.2 EUROPE
9.9.3 ASIA-PACIFIC
9.9.4 SOUTH AMERICA
9.9.5 MIDDLE EAST AND AFRICA
9.1 MIDDLE EAST AND AFRICA INFLIXIMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.10.1 NORTH AMERICA
9.10.2 EUROPE
9.10.3 ASIA-PACIFIC
9.10.4 SOUTH AMERICA
9.10.5 MIDDLE EAST AND AFRICA
9.11 MIDDLE EAST AND AFRICA TOFACITINIB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.11.1 NORTH AMERICA
9.11.2 EUROPE
9.11.3 ASIA-PACIFIC
9.11.4 SOUTH AMERICA
9.11.5 MIDDLE EAST AND AFRICA
9.12 MIDDLE EAST AND AFRICA OTHER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.12.1 NORTH AMERICA
9.12.2 EUROPE
9.12.3 ASIA-PACIFIC
9.12.4 SOUTH AMERICA
9.12.5 MIDDLE EAST AND AFRICA
10 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
10.2.1 SUBCUTANEOUS
10.2.2 ORAL
10.2.3 INTRAVENOUS
10.2.4 OTHERS
10.3 MIDDLE EAST AND AFRICA SUBCUTANEOUS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
10.3.1 NORTH AMERICA
10.3.2 EUROPE
10.3.3 ASIA-PACIFIC
10.3.4 SOUTH AMERICA
10.3.5 MIDDLE EAST AND AFRICA
10.4 MIDDLE EAST AND AFRICA ORAL IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
10.4.1 NORTH AMERICA
10.4.2 EUROPE
10.4.3 ASIA-PACIFIC
10.4.4 SOUTH AMERICA
10.4.5 MIDDLE EAST AND AFRICA
10.5 MIDDLE EAST AND AFRICA INTRAVENOUS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
10.5.1 NORTH AMERICA
10.5.2 EUROPE
10.5.3 ASIA-PACIFIC
10.5.4 SOUTH AMERICA
10.5.5 MIDDLE EAST AND AFRICA
10.6 MIDDLE EAST AND AFRICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
10.6.1 NORTH AMERICA
10.6.2 EUROPE
10.6.3 ASIA-PACIFIC
10.6.4 SOUTH AMERICA
10.6.5 MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
11.2.1 SPECIALTY CLINICS
11.2.2 HOMECARE
11.2.3 HOSPITALS
11.2.4 PHARMACY & RETAILERS
11.2.5 OTHERS
11.3 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
11.3.1 NORTH AMERICA
11.3.2 EUROPE
11.3.3 ASIA-PACIFIC
11.3.4 SOUTH AMERICA
11.3.5 MIDDLE EAST AND AFRICA
11.4 MIDDLE EAST AND AFRICA HOMECARE IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
11.4.1 NORTH AMERICA
11.4.2 EUROPE
11.4.3 ASIA-PACIFIC
11.4.4 SOUTH AMERICA
11.4.5 MIDDLE EAST AND AFRICA
11.5 MIDDLE EAST AND AFRICA HOSPITALS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
11.5.1 NORTH AMERICA
11.5.2 EUROPE
11.5.3 ASIA-PACIFIC
11.5.4 SOUTH AMERICA
11.5.5 MIDDLE EAST AND AFRICA
11.6 MIDDLE EAST AND AFRICA PHARMACY & RETAILERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
11.6.1 NORTH AMERICA
11.6.2 EUROPE
11.6.3 ASIA-PACIFIC
11.6.4 SOUTH AMERICA
11.6.5 MIDDLE EAST AND AFRICA
11.7 MIDDLE EAST AND AFRICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
11.7.1 NORTH AMERICA
11.7.2 EUROPE
11.7.3 ASIA-PACIFIC
11.7.4 SOUTH AMERICA
11.7.5 MIDDLE EAST AND AFRICA
12 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
12.2.1 HOSPITAL PHARMACY
12.2.2 RETAIL PHARMACY
12.2.3 DIRECT TENDER
12.2.4 ONLINE PHARMACY
12.2.5 OTHERS
12.3 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
12.3.1 NORTH AMERICA
12.3.2 EUROPE
12.3.3 ASIA-PACIFIC
12.3.4 SOUTH AMERICA
12.3.5 MIDDLE EAST AND AFRICA
12.4 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
12.4.1 NORTH AMERICA
12.4.2 EUROPE
12.4.3 ASIA-PACIFIC
12.4.4 SOUTH AMERICA
12.4.5 MIDDLE EAST AND AFRICA
12.5 MIDDLE EAST AND AFRICA DIRECT TENDER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
12.5.1 NORTH AMERICA
12.5.2 EUROPE
12.5.3 ASIA-PACIFIC
12.5.4 SOUTH AMERICA
12.5.5 MIDDLE EAST AND AFRICA
12.6 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
12.6.1 NORTH AMERICA
12.6.2 EUROPE
12.6.3 ASIA-PACIFIC
12.6.4 SOUTH AMERICA
12.6.5 MIDDLE EAST AND AFRICA
12.7 MIDDLE EAST AND AFRICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
12.7.1 NORTH AMERICA
12.7.2 EUROPE
12.7.3 ASIA-PACIFIC
12.7.4 SOUTH AMERICA
12.7.5 MIDDLE EAST AND AFRICA
13 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 U.A.E
13.1.4 ISRAEL
13.1.5 EGYPT
13.1.6 KUWAIT
13.1.7 QATAR
13.1.8 OMAN
13.1.9 BAHRAIN
13.1.10 REST OF MIDDLE EAST & AFRICA
14 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILE MANUFRACTURER
16.1 NOVARTIS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 PFIZER INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 ABBVIE INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 UCB S.A.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 LILLY
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BIOGEN
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 ALKEM
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 AMGEN INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 ASTELLAS PHARMA INC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 BIOCAD
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 BRISTOL-MYERS SQUIBB (BMS)
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 CELLTRION INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENTS
16.14 CIPLA
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 DR.REDDY’S LABORATORIES LTD.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 F. HOFFMANN-LA ROCHE LTD
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 FRESENIUS SE & CO. KGAA
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 GEDEON RICHTER PLC.
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENTS
16.19 JOHNSON & JOHNSON AND ITS AFFILIATES
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 KYOWA KIRIN CO., LTD.
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 LUPIN
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENTS
16.22 MERCK KGAA
16.22.1 COMPANY SNAPSHOT
16.22.2 REVENUE ANALYSIS
16.22.3 PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 SAMSUNG BIOEPIS
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENT
16.24 SANDOZ.INC
16.24.1 COMPANY SNAPSHOT
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENT
16.25 SANOFI
16.25.1 COMPANY SNAPSHOT
16.25.2 REVENUE ANALYSIS
16.25.3 PRODUCT PORTFOLIO
16.25.4 RECENT DEVELOPMENT
16.26 SUN PHARMACEUTICAL INDUSTRIES LTD.
16.26.1 COMPANY SNAPSHOT
16.26.2 REVENUE ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENTS
16.27 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENT
16.28 TEVA PHARMACEUTICAL INDUSTRIES LTD.
16.28.1 COMPANY SNAPSHOT
16.28.2 REVENUE ANALYSIS
16.28.3 PRODUCT PORTFOLIO
16.28.4 RECENT DEVELOPMENT
16.29 TORRENT PHARMACEUTICALS LTD.
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PRODUCT PORTFOLIO
16.29.4 RECENT DEVELOPMENTS
16.3 VIATRIS INC.
16.30.1 COMPANY SNAPSHOT
16.30.2 REVENUE ANALYSIS
16.30.3 PRODUCT PORTFOLIO
16.30.4 RECENT DEVELOPMENTS
16.31 ZYDUS GROUP
16.31.1 COMPANY SNAPSHOT
16.31.2 REVENUE ANALYSIS
16.31.3 PRODUCT PORTFOLIO
16.31.4 RECENT DEVELOPMENT
17 COMPANY PROFILE DISTRIBUTOR
17.1 ALFRESA PHARMA CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 ASTUTE HEALTHCARE LTD.
17.2.1 COMPANY SNAPSHOT
17.2.2 PRODUCT PORTFOLIO
17.2.3 RECENT DEVELOPMENT
17.3 CARDINAL HEALTH
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 CENCORA, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 MCKESSON CORPORATION
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 MEDIPAL HOLDINGS CORPORATION
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PHOENIX PHARMA SE
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 SMITH DRUG COMPANY
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 ZUELLIG PHARMA
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 COST BREAKDOWN (BIOLOGIC VS NON-BIOLOGIC THERAPY)
TABLE 2 DRUG COST BENCHMARKS (MIDDLE EAST AND AFRICA PRICING PERSPECTIVE)
TABLE 3 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA OTHER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA ADALIMUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA SECUKINUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA ETANERCEPT IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA IXEKIZUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA UPADACITINIB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA CERTOLIZUMAB PEGOL IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA GOLIMUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA INFLIXIMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA TOFACITINIB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA OTHER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA SUBCUTANEOUS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA ORAL IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA INTRAVENOUS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA HOMECARE IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA HOSPITALS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA PHARMACY & RETAILERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA DIRECT TENDER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA
TABLE 47 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 60 SAUDI ARABIA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 61 SAUDI ARABIA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 62 SAUDI ARABIA BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 63 SAUDI ARABIA TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 64 SAUDI ARABIA INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 65 SAUDI ARABIA JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 SAUDI ARABIA NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 67 SAUDI ARABIA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 68 SAUDI ARABIA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 69 SAUDI ARABIA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 70 SAUDI ARABIA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 71 SAUDI ARABIA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 72 SAUDI ARABIA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 73 SOUTH AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 74 SOUTH AFRICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 75 SOUTH AFRICA BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 76 SOUTH AFRICA TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 77 SOUTH AFRICA INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 78 SOUTH AFRICA JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 79 SOUTH AFRICA NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 80 SOUTH AFRICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 81 SOUTH AFRICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 82 SOUTH AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 83 SOUTH AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 84 SOUTH AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 85 SOUTH AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 86 U.A.E NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 87 U.A.E MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 88 U.A.E BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 89 U.A.E TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 90 U.A.E INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 91 U.A.E JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 U.A.E NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 93 U.A.E SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 94 U.A.E PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 95 U.A.E NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 96 U.A.E NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 97 U.A.E NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 98 U.A.E NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 99 ISRAEL NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 100 ISRAEL MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 101 ISRAEL BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 102 ISRAEL TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 103 ISRAEL INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 104 ISRAEL JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 105 ISRAEL NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 106 ISRAEL SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 107 ISRAEL PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 ISRAEL NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 109 ISRAEL NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 110 ISRAEL NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 111 ISRAEL NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 112 EGYPT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 113 EGYPT MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 114 EGYPT BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 115 EGYPT TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 116 EGYPT INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 117 EGYPT JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 118 EGYPT NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 119 EGYPT SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 120 EGYPT PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 121 EGYPT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 122 EGYPT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 123 EGYPT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 124 EGYPT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 125 KUWAIT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 126 KUWAIT MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 127 KUWAIT BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 128 KUWAIT TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 129 KUWAIT INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 130 KUWAIT JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 131 KUWAIT NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 132 KUWAIT SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 133 KUWAIT PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 134 KUWAIT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 135 KUWAIT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 136 KUWAIT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 137 KUWAIT NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 138 QATAR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 139 QATAR MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 140 QATAR BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 141 QATAR TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 142 QATAR INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 143 QATAR JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 144 QATAR NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 QATAR SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 146 QATAR PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 147 QATAR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 148 QATAR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 149 QATAR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 150 QATAR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 151 OMAN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 152 OMAN MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 153 OMAN BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 OMAN TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 155 OMAN INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 156 OMAN JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 157 OMAN NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 158 OMAN SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 159 OMAN PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 OMAN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 161 OMAN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 162 OMAN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 163 OMAN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 164 BAHRAIN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 165 BAHRAIN MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 166 BAHRAIN BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 167 BAHRAIN TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 168 BAHRAIN INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 169 BAHRAIN JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 170 BAHRAIN NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 171 BAHRAIN SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 172 BAHRAIN PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 173 BAHRAIN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 174 BAHRAIN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 175 BAHRAIN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 176 BAHRAIN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 177 REST OF MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 178 REST OF MIDDLE EAST AND AFRICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 179 REST OF MIDDLE EAST AND AFRICA BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 REST OF MIDDLE EAST AND AFRICA TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 REST OF MIDDLE EAST AND AFRICA INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 182 REST OF MIDDLE EAST AND AFRICA JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 183 REST OF MIDDLE EAST AND AFRICA NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 184 REST OF MIDDLE EAST AND AFRICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 185 REST OF MIDDLE EAST AND AFRICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 186 REST OF MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)
TABLE 187 REST OF MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 188 REST OF MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 189 REST OF MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: SEGMENTATION
FIGURE 12 FOUR SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE (2025)
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET AND ASIA PACIFIC IS GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2026 TO 2033
FIGURE 15 INCREASING PREVALENCE OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND IMPROVED DISEASE AWARENESS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2026 TO 2033
FIGURE 16 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET IN 2026 & 2033
FIGURE 18 PATENT VS IPC CODE
FIGURE 19 PATENT DISTRIBUTION COUNTRY WISE
FIGURE 20 PATENT DISTRIBUTION YEAR WISE
FIGURE 21 PATENT DISTRIBUTION APPLICANT WISE
FIGURE 22 DROC ANALYSIS
FIGURE 23 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY TREATMENT TYPE, 2025
FIGURE 24 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY TREATMENT TYPE, 2026 TO 2033 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY TREATMENT TYPE, CAGR (2026- 2033)
FIGURE 26 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DRUG, 2025
FIGURE 28 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DRUG, 2026 TO 2033 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DRUG, CAGR (2026- 2033)
FIGURE 30 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DRUG, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2025
FIGURE 32 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2026 TO 2033 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2026- 2033)
FIGURE 34 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY END USER, 2025
FIGURE 36 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY END USER, 2026 TO 2033 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY END USER, CAGR (2026- 2033)
FIGURE 38 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2025
FIGURE 40 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2026 TO 2033 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2026- 2033)
FIGURE 42 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: SNAPSHOT (2025)
FIGURE 44 MIDDLE EAST AND AFRICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: COMPANY SHARE 2025 (%)
